STOK / Stoke Therapeutics, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Stoke Therapeutics Second Quarter 2025 Business Update Webcast for Investors & Analysts August 12, 2025

Stoke Therapeutics Second Quarter 2025 Business Update Webcast for Investors & Analysts August 12, 2025 Long-Term 36-Month OLE Data Kimberly Parkerson, M.

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 7.01 Regulation FD. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commissio

Interim Chief Executive Officer Agreement, dated March 16, 2025, between Ian F. Smith and the Registrant.

Exhibit 10.2 March 16, 2025 Ian F. Smith Dear Ian: On behalf of Stoke Therapeutics, Inc. (the “Company”), this letter agreement (the “Agreement”) sets forth the terms and conditions of your appointment as Interim Chief Executive Officer of the Company. 1. Position; Continued Board Service. Effective as of March 19, 2025 (the “Start Date”), you will be appointed as the Company’s Interim Chief Execu

Interim Executive Chair Agreement, dated March 16, 2025, between Dr. Arthur O. Tzianabos, Ph.D. and the Registrant.

Exhibit 10.3 March 16, 2025 Arthur Tzianabos Dear Arthur: On behalf of Stoke Therapeutics, Inc. (the “Company”), this letter agreement (the “Agreement”) sets forth the terms and conditions of your appointment as Interim Executive Chairman of the Company’s Board of Directors. 1. Position; Continued Board Service. Effective as of March 19, 2025 (the “Start Date”), you will be appointed as the Compan

Transition and Separation Agreement, dated March 16, 2025, between Dr. Edward M. Kaye, M.D. and the Registrant.

Exhibit 10.1 March 16, 2025 VIA E-MAIL Edward Kaye Re: Terms of Resignation Dear Ed: This letter confirms the agreement (“Agreement”) between you and Stoke Therapeutics, Inc. (the “Company”) concerning the terms of your resignation and offers you the separation compensation we discussed in exchange for a general release of claims and covenant not to sue. 1. Resignation Date: March 19, 2025, is you

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.

Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates – First patient dosed in the Phase 3 EMPEROR study of zorevunersen in patients with Dravet syndrome – – New 3-year zorevunersen OLE data provide additional

EX 99.1 Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates – First patient dosed in the Phase 3 EMPEROR study of zorevunersen in patients with Dravet syndrome – – New 3-year zorevunersen OLE data provide additional support for disease modification: continuing and durable reductions in seizures and improvements in cognition and behavior and generally well

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 Stoke Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commissio

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome – Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compare

EX-99.1 Exhibit 99.1 Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome – Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period – – Dravet syndrome is a rare genetic disease characterized by refractory seizures and

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress – Data from an analysis designed to evaluate

Exhibit 99.1 Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress – Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 – – These findi

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2025 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission

Form of Debt Security

Exhibit 4.2 FORM OF DEBT SECURITY [Face of Security] STOKE THERAPEUTICS, INC. [If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS     % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS     % OF ITS PRINCIPAL AMOUNT, THE YIE

Filing Fee Table

EXHIBIT 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Stoke Therapeutics, Inc.

Amended and Restated 2023 Inducement Plan and forms of award agreements thereunder

EX-99.1 Exhibit 99.1 STOKE THERAPEUTICS, INC. 2023 INDUCEMENT PLAN AMENDED: JUNE 2, 2025 1. PURPOSE. The purpose of this Plan is to provide incentives to attract and motivate eligible employees whose present and potential contributions are important to the success of the Company, and any Parents, Subsidiaries, and Affiliates that exist now or in the future, by offering them an opportunity to parti

As filed with the Securities and Exchange Commission on July 9, 2025

S-8 As filed with the Securities and Exchange Commission on July 9, 2025 Registration No.

STOKE THERAPEUTICS, INC. 45 Wiggins Avenue Bedford, MA 01730 July 9, 2025

CORRESP STOKE THERAPEUTICS, INC. 45 Wiggins Avenue Bedford, MA 01730 July 9, 2025 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention:   Office of Life Sciences Re: Stoke Therapeutics, Inc. Registration Statement on Form S-3 Filed July 9, 2025 File No. 333-288583 Via EDGAR - Acceleration Request Requested Date:  July 11

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Fee Filing Tables Form S-3 (Form Type) Stoke Therapeutics, Inc.

As filed with the Securities and Exchange Commission on July 9, 2025.

Table of Contents As filed with the Securities and Exchange Commission on July 9, 2025.

Form of Indenture

Exhibit 4.3 STOKE THERAPEUTICS, INC. And         , as Trustee INDENTURE Dated as of     , TABLE OF CONTENTS ARTICLE 1 – DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 5 ARTICLE 2 – THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES

FORM OF DEBT SECURITY

Exhibit 4.2 FORM OF DEBT SECURITY [Face of Security] STOKE THERAPEUTICS, INC. [If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS     % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS     % OF ITS PRINCIPAL AMOUNT, THE YIE

STOKE THERAPEUTICS, INC.         , as Trustee Dated as of     ,

Exhibit 4.3 STOKE THERAPEUTICS, INC. And         , as Trustee INDENTURE Dated as of     , TABLE OF CONTENTS ARTICLE 1 – DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 5 ARTICLE 2 – THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES

Confidential Draft Submission No. 1 submitted to the Securities and Exchange Commission on June 26, 2025. This draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information herein remains str

Table of Contents Confidential Draft Submission No. 1 submitted to the Securities and Exchange Commission on June 26, 2025. This draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333-      UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGI

Fenwick & West LLP

DRSLTR Fenwick & West LLP 555 California Street 12th Floor San Francisco, CA 94104 June 26, 2025 CONFIDENTIAL SUBMISSION VIA EDGAR U.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2025 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission F

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission F

Forward-Looking Statements and Other Legal Notices This presentation has been prepared by Stoke Therapeutics, Inc. ( Stoke or us ) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be

Exhibit 99.1 Stoke Therapeutics NASDAQ: STOK June 2025 © © COP COPY YR RI IG GH HT T 2 20 02 25 5 | | S ST TOKE OKE T TH HER ERA AP PEU EUT TI ICS CS | | 1 Forward-Looking Statements and Other Legal Notices This presentation has been prepared by Stoke Therapeutics, Inc. ( Stoke or us ) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or shou

License and Collaboration Agreement, dated as of February 14, 2025, by and between Biogen International GmbH and the Registrant

Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED LICENSE AND COLLABORATION AGREEMENT by and between STOKE THERAPEUTICS, INC. and Biogen International GmbH Dated as of February 14, 2025 TABLE OF CONTENTS Page Article 1 DEFINITIONS 1 Artic

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.

Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates – Regulatory alignment achieved for Phase 3 EMPEROR study of zorevunersen, a potential first-in-class disease-modifying medicine for Dravet syndrome; Study

EX 99.1 Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates – Regulatory alignment achieved for Phase 3 EMPEROR study of zorevunersen, a potential first-in-class disease-modifying medicine for Dravet syndrome; Study start anticipated in 2Q 2025 – – Zorevunersen collaboration with Biogen brings leading capabilities for commercializing high value, disease-mo

2025 Non-Employee Director Compensation Policy

Exhibit 10.1 STOKE THERAPEUTICS, INC. (“Company”) Non-Employee Director Compensation Policy Approved as of September 9, 2024 (the “Approval Date”) Amended as of February 12, 2025 Each member of the Board of Directors (the “Board”) of Stoke Therapeutics, Inc. (the “Company”) who is a non-employee director of the Company (each such member, a “Non-Employee Director”) will receive the compensation des

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt

As filed with the Securities and Exchange Commission on March 18, 2025

As filed with the Securities and Exchange Commission on March 18, 2025 Registration No.

f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38938 Stoke Therape

Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates – Phase 3 EMPEROR study of zorevunersen, a first-in-class potential disease-modifying medicine for Dravet syndrome, on track to initiate in 2

EX.99.1 Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates – Phase 3 EMPEROR study of zorevunersen, a first-in-class potential disease-modifying medicine for Dravet syndrome, on track to initiate in 2Q 2025 – – As of December 31, 2024, the Company had $246.7 million in cash, cash equivalents, and marketable securities; together with the $16

Insider Trading Policy

Insider Trading Policy Policy Owner: Legal Department Effective Date: February 2, 2023 I.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission

Stoke Therapeutics Announces CEO Transition Edward M. Kaye, M.D., to Step Down as Chief Executive Officer Director Ian F. Smith Appointed Interim Chief Executive Officer Arthur Tzianabos Appointed Interim Executive Chairman of the Board Board of Dire

EX.99.2 Stoke Therapeutics Announces CEO Transition Edward M. Kaye, M.D., to Step Down as Chief Executive Officer Director Ian F. Smith Appointed Interim Chief Executive Officer Arthur Tzianabos Appointed Interim Executive Chairman of the Board Board of Directors Initiates Search for Permanent Chief Executive Officer BEDFORD, Mass., March 18, 2025 – Stoke Therapeutics, Inc. (Nasdaq: STOK) is a bio

Filing Fee Table

EXHIBIT 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Stoke Therapeutics, Inc.

Form of Irrevocable Payment Election for Non-Employee Directors

STOKE THERAPEUTICS, INC. CERTAIN CASH DIRECTOR FEES - FORM OF IRREVOCABLE PAYMENT ELECTION Name: Election Year: [ ] As a non-employee member of the board of directors (the “Board”) of Stoke Therapeutics, Inc. (the “Company”), you are entitled to receive cash fees pursuant to the Company’s Non-Employee Director Compensation Policy (as amended by the Board from time to time, the “Policy”). Pursuant

Exhibit 4.2

Exhibit 4.2 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 As of December 31, 2020, Stoke Therapeutics, Inc. (the “Company,” “we,” or “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock. The following description summarizes the mo

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments Stoke retains exclus

Exhibit 99.1 Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights Co

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2025 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commiss

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome – Alignment achieved with U.S. Food

Exhibit 99.1 Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome – Alignment achieved with U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for EMPEROR

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commissio

The Potential for Disease Modification in the Treatment of Dravet Syndrome: Clinical Data and Phase 3 Plan Barry Ticho, M.D., Ph.D., FACC, Chief Medical Officer Kimberly Parkerson, M.D., Ph.D., SVP, Head of Neurology Clinical Development Zorevunersen

Zorevunersen Regulatory Alignment & Phase 3 Plans Virtual Event for Investors & Analysts January 7, 2025 Exhibit 99.

Joint Filing Agreement

Exhibit 1 Joint Filing Agreement The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the Schedule 13D to which this Exhibit is attached, and such Schedule 13D is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2024 Stoke Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2024 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commissi

Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome – Substantial and durable reductions in convulsive seizure

Exhibit 99.2 Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome – Substantial and durable reductions in convulsive seizure frequency observed in patients treated with 2 or 3 doses of 70mg followed by 45mg maintenance dosing on top of the best available anti-se

Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome – Supported by evidence from clinical studies that indicate that zorevunersen may demonstrate substantial improvement over availabl

Exhibit 99.1 Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome – Supported by evidence from clinical studies that indicate that zorevunersen may demonstrate substantial improvement over available therapies – – Update on the company’s plans for a global, randomized, controlled Phase 3 registrational study anticipated by year-end –

AGREEMENT

EX-99.1 2 tm2426483d7ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Stoke Therapeutics, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. November 14, 2024 BAKER BROS. ADV

STOK / Stoke Therapeutics, Inc. / Lynx1 Capital Management LP - STOKE THERAPEUTICS, INC. Passive Investment

SC 13G/A 1 p24-3206sc13ga.htm STOKE THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Stoke Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 86150R107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Stateme

Joint Filing Agreement

EX-99.1 2 tm2427858d11ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, at $0.0

STOK / Stoke Therapeutics, Inc. / BAKER BROS. ADVISORS LP - SC 13G Passive Investment

SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No.

STOK / Stoke Therapeutics, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm2427858d11sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) Stoke therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 86150R107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 05, 2024 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commiss

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates – Company plans to provide seizure as well as cognition and behavior data from all patients treated with initial 70mg doses followed by 45mg maintenance dosing i

EX-99.1 Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates – Company plans to provide seizure as well as cognition and behavior data from all patients treated with initial 70mg doses followed by 45mg maintenance dosing in studies of zorevunersen by year-end – – Discussions with FDA and global regulatory agencies related to a single global Phase 3 study of zore

Form of Indenture

Exhibit 4.3 STOKE THERAPEUTICS, INC. And         , as Trustee INDENTURE Dated as of     , TABLE OF CONTENTS ARTICLE 1 – DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 4 ARTICLE 2 – THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES

As filed with the Securities and Exchange Commission on October 9, 2024

Table of Contents As filed with the Securities and Exchange Commission on October 9, 2024 Registration No.

Form of Debt Security

Exhibit 4.2 FORM OF DEBT SECURITY [Face of Security] STOKE THERAPEUTICS, INC. [If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS     % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS     % OF ITS PRINCIPAL AMOUNT, THE YIE

Filing Fee Table

EXHIBIT 107.1 CALCULATION OF FILING FEE TABLES Form S-3ASR (Form Type) Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Car

STOK / Stoke Therapeutics, Inc. / Skorpios Trust Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Stoke Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 86150R107 (CUSIP Number) Patrik Blochlinger Chief Legal Officer Rigmora (Switzerland) Ltd Stockerstrasse 8 8002 Zurich, Switzerland +41 44

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE GERALD J. ALSID, derivatively on behalf of STOKE THERAPEUTICS, INC., Plaintiff,   v. EDWARD M. KAYE, SETH L. HARRISON, ARTHUR O. TZIANABOS, ADRIAN R. KRAINER, GARRY E. MENZEL, JULIE ANNE SMITH, ARTHUR

Exhibit 99.1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE GERALD J. ALSID, derivatively on behalf of STOKE THERAPEUTICS, INC., Plaintiff,   v. EDWARD M. KAYE, SETH L. HARRISON, ARTHUR O. TZIANABOS, ADRIAN R. KRAINER, GARRY E. MENZEL, JULIE ANNE SMITH, ARTHUR A. LEVIN, JENNIFER C. BURSTEIN, and SAMUEL W. HALL, Defendants,   and STOKE THERAPEUTICS, INC., Nominal Defendant. ) ) ) ) ) ) ) ) ) ) )

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.

Executive Employment Agreement, by and between the Registrant and Thomas Leggett, effective as of April 23, 2024.

Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”), is made and entered into this 23rd day of April, 2024 (the “Effective Date”), by and between Stoke Therapeutics, Inc. (“Stoke”), and Thomas Leggett (“Executive”). WHEREAS, Stoke wishes to employ Executive to serve as its Chief Financial Officer; WHEREAS, Executive represents that Executive possesses

Change of Control Severance Agreement, by and between the Registrant and Thomas Leggett, effective as of April 23, 2024.

Exhibit 10.2 CHANGE OF CONTROL SEVERANCE AGREEMENT This Change of Control Severance Agreement (the “Agreement”), is made and entered into this 23rd day of April, 2024 (the “Effective Date”), by and between Stoke Therapeutics, Inc. (“Stoke”), and Thomas Leggett (“Executive”). Recitals: R-1. Stoke and Executive are parties to an Employment Agreement dated April 23, 2024 (the “Employment Agreement,”

Separation and Release Agreement, by and between the Registrant and Stephen J. Tulipano, dated May 2, 2024.

Exhibit 10.3 May 2, 2024 Stephen Tulipano Email: Re: Terms of Separation Dear Stephen: This letter confirms the agreement (“Agreement”) between you and Stoke Therapeutics, Inc. (the “Company”) concerning the terms of your separation and offers you the separation compensation we discussed in exchange for a general release of claims and covenant not to sue. 1. Separation Date; Resignation from Offic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2024 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commissio

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates – FDA removes Partial Clinical Hold as company advances toward a Phase 3 registrational study of zorevunersen (STK-001) in children and adolescents with Dravet

EX 99.1 Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates – FDA removes Partial Clinical Hold as company advances toward a Phase 3 registrational study of zorevunersen (STK-001) in children and adolescents with Dravet syndrome – – Company to provide an update on Phase 3 registrational plans for zorevunersen in the second half of 2024 – – Company on track to

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission

STOKE THERAPEUTICS, INC. 45 Wiggins Avenue Bedford, MA 01730 June 17, 2024

STOKE THERAPEUTICS, INC. 45 Wiggins Avenue Bedford, MA 01730 June 17, 2024 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Office of Life Sciences Re: Stoke Therapeutics, Inc. Registration Statement on Form S-3 Filed June 13, 2024 File No. 333-280172 Via EDGAR - Acceleration Request Requested Date:  June 20, 2024 R

As filed with the Securities and Exchange Commission on June 13, 2024

S-3 Table of Contents As filed with the Securities and Exchange Commission on June 13, 2024 Registration No.

Filing Fee Table.

Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) Stoke Therapeutics, Inc.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 06, 2024 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission F

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates – Recent data demonstrating reductions in seizure frequency and improvements in cognition and behavior support the potential for STK-001 as a disease-modifying p

EX 99.1 Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates – Recent data demonstrating reductions in seizure frequency and improvements in cognition and behavior support the potential for STK-001 as a disease-modifying potential medicine for the treatment of Dravet syndrome – – Company plans to meet with regulatory agencies to discuss registrational study desi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2024 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

STOK / Stoke Therapeutics, Inc. / Skorpios Trust Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

Filing Fee Table

EXHIBIT 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Stoke Therapeutics, Inc.

As filed with the Securities and Exchange Commission on April 11, 2024

S-8 As filed with the Securities and Exchange Commission on April 11, 2024 Registration No.

Underwriting Agreement dated March 27, 2024, by and between the Company and J.P. Morgan Securities LLC.

Exhibit 1.1 Execution Version Stoke Therapeutics, Inc. 5,555,557 Shares of Common Stock and Pre-Funded Warrants to Purchase 3,703,730 Shares of Common Stock Underwriting Agreement March 27, 2024 J.P. Morgan Securities LLC As Representative of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: Stoke T

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission

Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering

Exhibit 99.1 Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering BEDFORD, Mass., March 27, 2024 (BUSINESS WIRE) – Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the pricing of its upsized underwritten public offering

Common Stock Pre-funded Warrants to Purchase Shares of Common Stock

Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated March 27, 2024 Relating to Preliminary Prospectus Supplement Dated March 26, 2024 Registration Statement No.

Sole Book-Running Manager J.P. Morgan

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-265107 Prospectus supplement (To prospectus dated May 31, 2022) 5,555,557 shares of Common Stock Pre-funded Warrants to Purchase 3,703,730 Shares of Common Stock Common stock We are offering 5,555,557 shares of our common stock, par value $0.0001 per share and, in lieu of common stock to certain investors that so choose, pre-f

Form of Pre-Funded Warrant.

Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [   ] (subject to adjustment) Warrant No.   Original Issue Date: April 2, 2024 STOKE THERAPEUCTICS, INC. Stoke Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered ass

Sole Book-Running Manager J.P. Morgan

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-265107 This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, as amended, but the information in this prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus a

Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results – As of December 31, 2023, Company had $201.4 million in cash, cash equivalents, and marketable securities, anticipated to fund operations to the end of 2025 –

EX 99.1 Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results – As of December 31, 2023, Company had $201.4 million in cash, cash equivalents, and marketable securities, anticipated to fund operations to the end of 2025 – BEDFORD, Mass., March 25, 2024 – Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe

Compensation Recovery Policy

Exhibit 97 Stoke Therapeutics, Inc. Compensation Recovery Policy (Adopted September 19, 2023) The Board has determined that it is in the best interests of the Company and its stockholders to adopt this Policy enabling the Company to recover from specified current and former Company executives certain incentive-based compensation in the event of an accounting restatement resulting from material non

Restated Certificate of Incorporation of the Registrant, as amended

Exhibit 3.1 STOKE THERAPEUTICS, INC. RESTATED CERTIFICATE OF INCORPORATION Stoke Therapeutics, Inc., a Delaware corporation, hereby certifies as follows: 1. The name of the corporation is “Stoke Therapeutics, Inc.” The date of the filing of its original Certificate of Incorporation with the Secretary of State was June 13, 2014 under the name ASOthera Pharmaceuticals, Inc. 2. The Restated Certifica

Lease Agreement, dated as of September 8, 2021, by and between ARE-MA Region No. 24, LLC and the Registrant, as amended to date.

Exhibit 10.12 LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”) is made this 8 day of September, 2021, between ARE‑MA REGION NO. 24, LLC, a Delaware limited liability company (“Landlord”), and STOKE THERAPEUTICS, INC., a Delaware corporation (“Tenant”). Building: 45-47 Wiggins Avenue, Bedford, MA 01730 Premises: That portion of (i) the Building known as Suite 200, containing approximately 23,000

Description of Common Stock Registered Under Section 12 of the Securities Exchange Act of 1934.

Exhibit 4.2 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 As of December 31, 2020, Stoke Therapeutics, Inc. (the “Company,” “we,” or “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock. The following description summarizes the mo

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission

f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38938 Stoke Therape

Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome – Phase 1/2a End of Study Data: 70mg doses demonstrated substantial an

Exhibit 99.1 Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome – Phase 1/2a End of Study Data: 70mg doses demonstrated substantial and sustained reductions in convulsive seizure frequency on top of the best available anti-seizure medicines; Median reductions of 85% (n=1

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission

Agenda Introduction Eric Rojas, Head of Investor Relations Introductory Remarks Edward M. Kaye, M.D., Chief Executive Officer Analysis of Phase 1/2a and Open-Label Extension (OLE) Studies of STK-001 Barry Ticho, M.D., Ph.D., Chief Medical Officer Kim

Analysis of STK-001 for the Treatment of Dravet Syndrome Stoke Therapeutics March 25, 2024 Exhibit 99.

STOK / Stoke Therapeutics, Inc. / Cowen Financial Products LLC - COWEN FINANCIAL PRODUCTS LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Stoke Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 86150R107 (CUSIP Number) December 29, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi

STOK / Stoke Therapeutics, Inc. / Cowen Financial Products LLC - COWEN FINANCIAL PRODUCTS LLC Passive Investment

SC 13G 1 stok22624.htm COWEN FINANCIAL PRODUCTS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Stoke Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 86150R107 (CUSIP Number) January 04, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat

STOK / Stoke Therapeutics, Inc. / Lynx1 Capital Management LP - STOKE THERAPEUTICS, INC. Passive Investment

SC 13G/A 1 p24-0771sc13ga.htm STOKE THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Stoke Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 86150R107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statemen

STOK / Stoke Therapeutics, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm245846d12sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3) Stoke therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 86150R107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check t

STOK / Stoke Therapeutics, Inc. / RTW INVESTMENTS, LP - STOKE THERAPEUTICS, INC. Passive Investment

SC 13G/A 1 p24-0444sc13ga.htm STOKE THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Stoke Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 86150R107 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statemen

Joint Filing Agreement

EX-99.1 2 tm245846d12ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, at $0.00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Stoke Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commissio

Disclaimer This presentation has been prepared by Stoke Therapeutics, Inc. ( Stoke or us ) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise

EX-99.1 Exhibit 99.1 Stoke Therapeutics NASDAQ: STOK Edward M. Kaye, M.D. Chief Executive Officer nd 42 Annual J.P. Morgan Healthcare Conference January 10, 2024 © Copyr ©i g Ch op t 2024 yrightS 2024 toke T Sh tok era ep T e h u e tr ic as peutic1 s Disclaimer This presentation has been prepared by Stoke Therapeutics, Inc. ( Stoke or us ) for informational purposes only and not for any other purp

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 3) (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 STOKE THERAPEUTICS, INC. (Name of Su

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 3) (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 STOKE THERAPEUTICS, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 86150

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2023 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commissi

Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting – Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages

Exhibit 99.1 Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting – Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease mo

Form of Reminder Email to Eligible Employees Regarding the Exchange Offer Deadline

EX-99.(a)(1)(D) Exhibit (a)(1)(D) As an Eligible Employee in Stoke Therapeutics’ Exchange Program to exchange Eligible Options for New RSUs (restricted stock units), we are pleased to inform you that the Exchange Offer is still open and you can make or change your election(s) until the Exchange Offer expires at 11:59 p.m., Eastern Daylight Time, on December 1, 2023. To access the Exchange Program

* * * * * * *

Julia Forbess [email protected] | 415.875.2420 November 17, 2023 VIA EDGAR AND OVERNIGHT DELIVERY U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Christina Chalk Shane Callaghan Re: Stoke Therapeutics, Inc. Schedule TO-I Filed November 2, 2023 File No. 005-91051 Ladies and Gentlemen: On behalf of St

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 2) (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 STOKE THERAPEUTICS, INC. (Name of Su

SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 2) (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 STOKE THERAPEUTICS, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 1) (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 STOKE THERAPEUTICS, INC. (Name of Subj

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 1) (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 STOKE THERAPEUTICS, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 86150R1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2023 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commiss

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates – STK-001: Q1 2024 readout expected to include end of Phase 1/2a study results and longer-term data on the effects of repeat dosing on seizure frequency, cogniti

EX 99.1 Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates – STK-001: Q1 2024 readout expected to include end of Phase 1/2a study results and longer-term data on the effects of repeat dosing on seizure frequency, cognition, and behavior from the ongoing open-label extension (OLE) studies – – STK-001: Company then plans to meet with regulators to discuss a Phas

STOK / Stoke Therapeutics Inc / Lynx1 Capital Management LP - STOKE THERAPEUTICS, INC. Passive Investment

SC 13G 1 p23-2664sc13g.htm STOKE THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Stoke Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 86150R107 (CUSIP Number) October 26, 2023 (Date of Event Which Requires Filing of this Statement) Chec

JOINT FILING AGREEMENT

EX-99.1 2 p23-2664exhibit99.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agr

Offer to Exchange Eligible Options for New Restricted Stock Units, dated November 2, 2023

EX-99.(a)(1)(A) Exhibit (a)(1)(A) NOVEMBER 2, 2023 STOKE THERAPEUTICS, INC. SUMMARY TERM SHEET — OVERVIEW OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW RESTRICTED STOCK UNITS THIS OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 P.M., EASTERN TIME, ON DECEMBER 1, 2023, UNLESS EXTENDED By this Offer to Exchange Eligible Options for restricted stock units (as the context requires, this document and the

Screenshots from Exchange Offer Website

EX-99.(a)(1)(F) Exhibit (a)(1)(F) Website Screenshots Document Library page – more documents will be listed as needed

Form of Frequently Asked Questions

EX-99.(a)(1)(E) Exhibit (a)(1)(E) What is the Offer to Exchange Eligible Options for Restricted Stock Units (RSUs)? The exchange offer (the “Exchange Offer”) is an offer for Eligible Employees (as defined below) to exchange significantly out-of-the-money or “underwater” stock options for new restricted stock units (“RSUs”) on an approximately value-neutral basis. Who is eligible to participate in

Story Boards for Employee Education Videos

EX-99.(a)(1)(G) Exhibit (a)(1)(G) Scene 1 (00m00s - 00m06s) Description: equitv.aon.com/viewer/StokeTherapeutics23/UWSO/1a1672bbf 8df4236 Words on screen: Stoke Therapeutics Option Exchange Program Overview Storyboard: Stoke Therapeutics | UWSO | StokeTherapeutics’ Option Exchange Program Overview (2023) Scene 2 (00m06s - 00m11s) Script: Welcome to this video that will explain the Stoke Therapeuti

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Schedule TO-I (Form Type) Stoke Therapeutics, Inc.

Form of Email Confirming Receipt of Election(s)

EX-99.(a)(1)(C) Exhibit (a)(1)(C)

Script for Power Point Deck

EX-99.(a)(1)(I) Exhibit (a)(1)(I) Stoke Therapeutics – Stock Option Exchange Program Presentation Introduction: Good afternoon everyone, and thank you for joining us today for a presentation about Stoke’s stock option exchange program. As many of you know, I am Jon Allan, General Counsel here at Stoke, and I am joined today by John Hammond from our advisors at Aon who will walk you through the exc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 STOKE THERAPEUTICS, INC. (Name of Subject Company (Issue

SC TO-I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 STOKE THERAPEUTICS, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 86150R107 (CUSIP

Stoke Therapeutics Stock Option Exchange Program PowerPoint Deck

EX-99.(a)(1)(H) Exhibit (a)(1)(H) Stoke Therapeutics Stock Option Exchange Program November 2023 © Copyr © igh Cot p2023 yrigh t S2023 toke T Sh to er ke ap T eh ue tic ras peutics 1 Agenda • Introductions and Overview • The Basics • How an Option Exchange Works • Eligibility • RSU Terms • Considering Your Choice • Important Disclaimers • Q&A © Copyright 2023 Stoke Therapeutics 2 Quick Intro • Joh

Form of Announcement to Eligible Employees that Exchange Program has Opened

EX-99.(a)(1)(B) Exhibit (a)(1)(B) We are pleased to announce that Stoke Therapeutics’ Option Exchange Program opens today. You are receiving this email because you are eligible to exchange certain underwater options for a fewer number of new Restricted Stock Units (RSUs) with a substantially similar value. The Exchange Offer is currently scheduled to remain open through 11:59 p.m., Eastern Dayligh

Form of Reminder Email to Eligible Employees Regarding the Exchange Offer Deadline

EX-99.(a)(1)(D) Exhibit (a)(1)(D) As an Eligible Employee in Stoke Therapeutics’ Exchange Program to exchange Eligible Options for New RSUs (restricted stock units), we are pleased to inform you that the Exchange Offer is still open and you can make or change your election(s) until the Exchange Offer expires at 11:59 p.m., Eastern Daylight Time, on December 1, 2023. To access the Exchange Program

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organiz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2023 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commis

Stoke Therapeutics Appoints Ian Smith to its Board of Directors – Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases –

Exhibit 99.1 Stoke Therapeutics Appoints Ian Smith to its Board of Directors – Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases – BEDFORD, Mass., September 20, 2023 – Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protei

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2023 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commissio

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates – STK-001: Additional data from patients treated with single and multiple doses (70mg) along with data from open-label extension studies (30mg, 45mg) anticipate

EX 99.1 Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates – STK-001: Additional data from patients treated with single and multiple doses (70mg) along with data from open-label extension studies (30mg, 45mg) anticipated in Q1 2024 – – STK-001: Company plans to share an update on Phase 3 planning in 1H 2024 – – STK-002: Company received authorization to initi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2023 Stoke Therapeutics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2023 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organizati

Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome –

EX-99.1 Exhibit 99.1 Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome – Totality of data from these ongoing studies suggest clinical benefit for patients ages 2 to 18 years old, including reductions in

Agenda Introduction Eric Rojas, Head of Investor Relations Introductory Remarks Edward M. Kaye, M.D., Chief Executive Officer Phase 1/2a Interim Analysis Barry Ticho, M.D., Ph.D., Chief Medical Officer Kimberly Parkerson, M.D., Ph.D., Head of Neurolo

EX-99.2 Analysis of STK-001 for the Treatment of Dravet Syndrome Stoke Therapeutics July 25, 2023 Exhibit 99.2 Agenda Introduction Eric Rojas, Head of Investor Relations Introductory Remarks Edward M. Kaye, M.D., Chief Executive Officer Phase 1/2a Interim Analysis Barry Ticho, M.D., Ph.D., Chief Medical Officer Kimberly Parkerson, M.D., Ph.D., Head of Neurology Clinical Development Closing Remarks

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 Stoke Therapeutics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organizati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates – Company on-track to report new data from the ongoing Phase 1/2a clinical studies of STK-001 in children and adolescents with Dravet syndrome in mid-2023 – – Da

EX 99.1 Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates – Company on-track to report new data from the ongoing Phase 1/2a clinical studies of STK-001 in children and adolescents with Dravet syndrome in mid-2023 – – Data readout will focus on safety and seizure frequency results for up to 16 patients who received three doses of 45mg of STK-001 – – Company pl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.

Registration Rights Agreement, by and among the Registrant, Blue Horizon Enterprise Ltd. and Ezbon International Limited, dated May 3, 2023.

Exhibit 4.1 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made as of May 3, 2023 by and among Stoke Therapeutics, Inc. a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 04, 2023 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (

2023 Inducement Plan, and forms of award agreements.

EX-99.1 Exhibit 99.1 STOKE THERAPEUTICS, INC. 2023 INDUCEMENT PLAN 1. PURPOSE. The purpose of this Plan is to provide incentives to attract and motivate eligible employees whose present and potential contributions are important to the success of the Company, and any Parents, Subsidiaries, and Affiliates that exist now or in the future, by offering them an opportunity to participate in the Company’

Filing Fees Table

EX-FILING FEES Exhibit 107.1 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Commo

As filed with the Securities and Exchange Commission on April 13, 2023

As filed with the Securities and Exchange Commission on April 13, 2023 Registration No.

As filed with the Securities and Exchange Commission on March 22, 2023

S-8 As filed with the Securities and Exchange Commission on March 22, 2023 Registration No.

Filing Fee Table

Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par val

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organizat

Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome – Dosing anticipated to start in the coming weeks –

EX-99.1 Exhibit 99.1 Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome – Dosing anticipated to start in the coming weeks – – Company remains on track for its planned data readouts from the Phase 1/2a MONARCH and ADMIRAL studies in 2023 – BEDFORD, Mass

2019 Equity Incentive Plan and forms of award agreements thereunder

Exhibit 10.3 STOKE THERAPEUTICS, INC. 2019 EQUITY INCENTIVE PLAN 1. PURPOSE. The purpose of this Plan is to provide incentives to attract, retain, and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents, Subsidiaries, and Affiliates that exist now or in the future, by offering them an opportunity to participate in the Com

Form 10-K

f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38938 Stoke Therape

Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates – Company expects to complete Phase 1/2a studies of STK-001 in children and adolescents with Dravet syndrome in 2023 in order to initiate a P

Exhibit 99.1 Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates – Company expects to complete Phase 1/2a studies of STK-001 in children and adolescents with Dravet syndrome in 2023 in order to initiate a Phase 3 program in 2024 – – Company on track to provide additional safety and seizure frequency data from patients who received multiple 4

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organizati

STOK / Stoke Therapeutics Inc / RTW INVESTMENTS, LP - STOKE THERAPEUTICS, INC. Passive Investment

SC 13G/A 1 p23-0490sc13ga.htm STOKE THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Stoke Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 86150R107 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement

STOK / Stoke Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Stoke Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 86150R107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is file

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2023 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organiz

Restated Bylaws of the Registrant

Exhibit 3.1 STOKE THERAPEUTICS, INC. (a Delaware corporation) AMENDED AND RESTATED BYLAWS As Amended and Restated on February 2, 2023 STOKE THERAPEUTICS, INC. (a Delaware corporation) AMENDED AND RESTATED BYLAWS TABLE OF CONTENTS Article I: STOCKHOLDERS 5 Section 1.1: Annual Meetings 5 Section 1.2: Special Meetings 5 Section 1.3: Notice of Meetings 5 Section 1.4: Adjournments 5 Section 1.5: Quorum

STOK / Stoke Therapeutics Inc / Redmile Group, LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm235383d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2) Stoke therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 86150R107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check th

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, at $0.0001 par value per share, of Stoke Therapeutics

STOK / Stoke Therapeutics Inc / Cowen Financial Products LLC - COWEN FINANCIAL PRODUCTS LLC Passive Investment

SC 13G/A 1 stoka112523.htm COWEN FINANCIAL PRODUCTS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Stoke Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 86150r107 (CUSIP Number) December 30, 2022 (Date of Event which Requires Filing of this Statement) Check the app

Disclaimer This presentation has been prepared by Stoke Therapeutics, Inc. ( Stoke or us ) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise

EX-99.1 2 d427248dex991.htm EX-99.1 Exhibit 99.1 Stoke Therapeutics NASDAQ: STOK Edward M. Kaye, M.D. Chief Executive Officer st 41 Annual J.P. Morgan Healthcare Conference January 10, 2023 © Copy © Copy right 20 ri23 ght S20 toke 23 Therape Stoke Therape utics utic1 s Disclaimer This presentation has been prepared by Stoke Therapeutics, Inc. ( Stoke or us ) for informational purposes only and not

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organiza

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2022 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organiz

Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting – Single and multip

Exhibit 99.1 Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting ? Single and multiple doses of STK-001 up to 45mg were well-tolerated ? ? 55% median reduction from baseline in convulsive seizure frequency was observed am

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates – Company announces positive interim data from the ongoing Phase 1/2a clinical studies of STK-001 in children and adolescents with Dravet syndrome – – Single and

Exhibit 99.1 Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates ? Company announces positive interim data from the ongoing Phase 1/2a clinical studies of STK-001 in children and adolescents with Dravet syndrome ? ? Single and multiple doses of STK-001 up to 45mg were well-tolerated ? ? 55% median reduction from baseline in convulsive seizure frequency was obse

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Stoke Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.

Agenda Introduction Eric Rojas, Head of Investor Relations Introductory Remarks Edward M. Kaye, M.D., Chief Executive Officer Phase 1/2a Interim Analysis Barry Ticho, M.D., Ph.D., Chief Medical Officer Closing Remarks Edward M. Kaye, M.D., Chief Exec

Interim Analysis of STK-001 for the Treatment of Dravet Syndrome Stoke Therapeutics November 14, 2022 Exhibit 99.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates – In the fourth quarter, the Company plans to announce interim safety, pharmacokinetic (PK), and cerebrospinal fluid (CSF) drug exposure data from approximately

Exhibit 99.1 Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates ? In the fourth quarter, the Company plans to announce interim safety, pharmacokinetic (PK), and cerebrospinal fluid (CSF) drug exposure data from approximately 40 patients in the ongoing clinical studies of STK-001 in children and adolescents with Dravet syndrome ? ? Analysis will also include s

Scientific Advisory Board Agreement by and between the Registrant and Adrian Krainer, Ph.D., dated June 1, 2022.

Exhibit 10.1 STOKE THERAPEUTICS, INC. SCIENTIFIC ADVISORY BOARD AGREEMENT This SCIENTIFIC ADVISORY BOARD Agreement (this ?Agreement?) is entered into as of June 1, 2022 (the ?Effective Date?) between Stoke Therapeutics, Inc., a Delaware corporation having offices at 45 Wiggins Avenue, Bedford, MA 01730 (?Stoke?) and Adrian Krainer, Ph.D. (?Advisor?). Advisor has unique skills and knowledge pertine

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organizat

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organizatio

STOKE THERAPEUTICS, INC. 45 Wiggins Avenue Bedford, MA 01730 May 26, 2022

STOKE THERAPEUTICS, INC. 45 Wiggins Avenue Bedford, MA 01730 May 26, 2022 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Office of Life Sciences Re: Stoke Therapeutics, Inc. Registration Statement on Form S-3 Filed May 20, 2022 File No. 333-265107 Via EDGAR - Acceleration Request Requested Date: May 31, 2022 Reque

Form of Debt Security

Exhibit 4.3 FORM OF DEBT SECURITY [Face of Security] STOKE THERAPEUTICS, INC. [If applicable, insert?FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS ?PRINCIPAL AMOUNT?), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIELD TO MA

Filing Fee Table

Exhibit 107 Calculation of Fee Filing Tables Form S-3 (Form Type) Stoke Therapeutics, Inc.

Form of Indenture

Exhibit 4.4 STOKE THERAPEUTICS, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 ? DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 4 ARTICLE 2 ? THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES 5 2.3. EXEC

As filed with the Securities and Exchange Commission on May 20, 2022

Table of Contents As filed with the Securities and Exchange Commission on May 20, 2022 Registration No.

Controlled Equity OfferingSM Sales Agreement, dated May 20, 2022, by and between the Registrant and Cantor Fitzgerald & Co.

Exhibit 1.2 STOKE THERAPEUTICS, INC. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement May 20, 2022 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Stoke Therapeutics, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cantor Fitzgerald & Co. (the ?Agent?), as follows: 1. Issu

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2022 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organizatio

License and Collaboration Agreement, dated as of January 9, 2022, by and between Acadia Pharmaceuticals Inc. and the Registrant.

Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED Execution Version LICENSE AND COLLABORATION AGREEMENT by and between Stoke Therapeutics, Inc. and Acadia Pharmaceuticals Inc. January 9, 2022 Execution Version LICENSE AND COLLABORATION AG

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organizatio

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates – 2H 2022 clinical data readout on track for patients with Dravet syndrome who received multiple doses of STK-001 (30mg) in Phase 1/2a clinical studies MONARCH,

Exhibit 99.1 Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates ? 2H 2022 clinical data readout on track for patients with Dravet syndrome who received multiple doses of STK-001 (30mg) in Phase 1/2a clinical studies MONARCH, ADMIRAL, and SWALLOWTAIL ? ? Recent preclinical data support ongoing development of STK-002 as the first potential disease-modifying appr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

X` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A 1 d295502ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Prox

Definitive Proxy Statement

DEF 14A 1 d295502ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confident

As filed with the Securities and Exchange Commission on March 14, 2022

As filed with the Securities and Exchange Commission on March 14, 2022 Registration No.

Filing Fee Table

Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 ? Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.000

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organizat

Scientific Advisory Board Agreement by and between the Registrant and Adrian Krainer, Ph.D., dated June 1, 2021

Exhibit 10.13 STOKE THERAPEUTICS, INC. SCIENTIFIC ADVISORY BOARD AGREEMENT This SCIENTIFIC ADVISORY BOARD Agreement (this ?Agreement?) is entered into as of June 1, 2021 (the ?Effective Date?) between Stoke Therapeutics, Inc., a Delaware corporation having offices at 45 Wiggins Avenue, Bedford, MA 01730 (?Stoke?) and Adrian Krainer, Ph.D. (?Advisor?). Advisor has unique skills and knowledge pertin

s UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

s UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38938 Stoke Therape

Stoke Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates – Enrollment and dosing ongoing in the Phase 1/2a MONARCH and ADMIRAL studies of STK-001 in children and adolescents with Dravet syndrome – –

Exhibit 99.1 Stoke Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates ? Enrollment and dosing ongoing in the Phase 1/2a MONARCH and ADMIRAL studies of STK-001 in children and adolescents with Dravet syndrome ? ? Company remains on track to provide additional clinical data in 2H 2022 from patients treated with multiple ascending doses of STK-001 a

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2022 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organi

STOK / Stoke Therapeutics Inc / Redmile Group, LLC - SCHEDULE 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) STOKE THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 86150R107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, at $0.0001 par value per share, of Stoke Therapeutics

STOK / Stoke Therapeutics Inc / RTW INVESTMENTS, LP - STOKE THERAPEUTICS, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Stoke Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 86150R107 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursu

STOK / Stoke Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Stoke Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 86150R107 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 13d-1(b) ?

STOK / Stoke Therapeutics Inc / Cowen Financial Products LLC - COWEN FINANCIAL PRODUCTS LLC Passive Investment

SC 13G 1 stok12422.htm COWEN FINANCIAL PRODUCTS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Stoke Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 86150r107 (CUSIP Number) January 19, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat

Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases - Establishes co-development and co-commercialization agreement for Stoke’s SYNGAP1 p

Exhibit 99.2 Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases - Establishes co-development and co-commercialization agreement for Stoke?s SYNGAP1 preclinical program - Acadia receives exclusive worldwide licenses for two additional preclinical programs: Rett syndrome (MECP2) and undi

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2022 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organiza

Disclaimer This presentation has been prepared by Stoke Therapeutics, Inc. (“Stoke” or “our”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promi

Exhibit 99.1 Stoke Therapeutics NASDAQ: STOK Edward M. Kaye, M.D. Chief Executive Officer th 40 Annual J.P. Morgan Healthcare Conference January 10, 2022 ? Copyr ? igh Cot p2022 yrigh t S2022 toke T Sh to er ke ap T eh ue tic ras peutics 1 Disclaimer This presentation has been prepared by Stoke Therapeutics, Inc. (?Stoke? or ?our?) for informational purposes only and not for any other purpose. Not

Amendment to Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organi

Stoke Therapeutics Presents Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2021 Annual Meeting – Single doses of STK-001 up to 30mg and multiple doses of 20mg

Exhibit 99.1 Stoke Therapeutics Presents Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2021 Annual Meeting ? Single doses of STK-001 up to 30mg and multiple doses of 20mg were well tolerated with no safety concerns related to study drug ? ? 70.6% (12/17) of patients treated with STK-001 experienced a reduct

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2021 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organiz

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates – Company nominates STK-002 as clinical candidate for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder –

Exhibit 99.1 Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates ? Company nominates STK-002 as clinical candidate for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder ? ? Additional data from an interim analysis of the Phase 1/2a MONARCH study of STK-001 including 20mg multiple ascending dose (MAD) seizur

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organiz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.

Lease Agreement, dated as of September 8, 2021, by and between ARE-MA Region No. 24, LLC and the Registrant.

Exhibit 10.1 LEASE AGREEMENT THIS LEASE AGREEMENT (this ?Lease?) is made this 8 day of September, 2021, between ARE?MA REGION NO. 24, LLC, a Delaware limited liability company (?Landlord?), and STOKE THERAPEUTICS, INC., a Delaware corporation (?Tenant?). Building: 45-47 Wiggins Avenue, Bedford, MA 01730 Premises: That portion of (i) the Building known as Suite 200, containing approximately 23,000

Amendment to Sublease dated as of September 8, 2021, by and between Homology Medicines, Inc., and the Registrant.

Exhibit 10.2 AMENDMENT TO SUBLEASE THIS AMENDMENT TO SUBLEASE (this ?Amendment?) is dated as of September 8, 2021 (the ?Effective Date?) by and between Homology Medicines, Inc., a Delaware corporation (?Sublessor?), and Stoke Therapeutics, Inc., a Delaware corporation ("Subtenant"). Capitalized terms used but not defined in this Amendment shall have the meanings ascribed to them in the Sublease. R

Agenda Introduction Eric Rojas, Head of Investor Relations Disease Overview, Patient Need, and STK-001 Mechanism of Action Edward M. Kaye, M.D., Chief Executive Officer Phase 1/2a MONARCH Interim Analysis Barry Ticho, M.D., Ph.D., Chief Medical Offic

MONARCH study in Dravet Syndrome Interim Analysis September 21, 2021 Exhibit 99.1 Agenda Introduction Eric Rojas, Head of Investor Relations Disease Overview, Patient Need, and STK-001 Mechanism of Action Edward M. Kaye, M.D., Chief Executive Officer Phase 1/2a MONARCH Interim Analysis Barry Ticho, M.D., Ph.D., Chief Medical Officer Closing Remarks Edward M. Kaye, M.D., Chief Executive Officer Q&A

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2021 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organ

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2021 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organi

Lease Agreement, by and between MIT 139 Main Street Leasehold LLC, and the Registrant., as amended to date.

EXHIBIT 10.1 139 Main street CAMBRIDGE, MASSACHUSETTS LEASE SUMMARY SHEET Execution Date: January 2, 2019 Tenant: Stoke Therapeutics, Inc. a Delaware corporation Tenant?s Mailing Address Prior to Occupancy: 3 Preston Court Suite 102 Bedford, MA 01730 Landlord: MIT 139 Main Street Leasehold LLC, a Massachusetts limited liability company Building: 139 Main Street, Cambridge, Massachusetts. The Build

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates – Dosing up to 30mg complete in the single ascending dose (SAD) portion in the Phase 1/2a MONARCH study of STK-001 in children and adolescents with Dravet syndr

Exhibit 99.1 Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates ? Dosing up to 30mg complete in the single ascending dose (SAD) portion in the Phase 1/2a MONARCH study of STK-001 in children and adolescents with Dravet syndrome; Enrollment and dosing in the multiple ascending dose (MAD) portion ongoing ? ? Third quarter data readout will include 3-month safet

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organiza

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.

STOK / Stoke Therapeutics Inc / Skorpios Trust Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

STOK / Stoke Therapeutics Inc / ATP Life Science Ventures, L.P. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Stoke Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 86150R107 (CUSIP Number) Daniel P. Finkelman General Counsel Apple Tree Partners 230 Park Avenue, 28th Floor New York, NY 10169 (212) 468

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2021 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organizatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No.

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates – Enrollment complete in single ascending dose (SAD) portion (10mg, 20mg, 30mg) of Phase 1/2a MONARCH study of STK-001 in children and adolescents with Dravet sy

Exhibit 99.1 Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates ? Enrollment complete in single ascending dose (SAD) portion (10mg, 20mg, 30mg) of Phase 1/2a MONARCH study of STK-001 in children and adolescents with Dravet syndrome; Interim analysis planned for the third quarter ? ? Enrollment and dosing ongoing in the 20mg multiple ascending dose (MAD) portio

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38938 Stoke Therapeutics, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organizatio

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Ru

- DEF 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (

- S-8

As filed with the Securities and Exchange Commission on March 19, 2021 Registration No.

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38938 Stoke Therapeut

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2021 Stoke Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38938 47-1144582 (State or other jurisdiction of incorporation or organizati

Description of Common Stock Registered Under Section 12 of the Securities Exchange Act of 1934.

Exhibit 4.3 Description of the Registrant?s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 As of December 31, 2020, Stoke Therapeutics, Inc. (the ?Company,? ?we,? or ?our?) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our common stock. The following description summarizes the mo

Change of Control and Severance Agreement, by and between the Registrant and Barry Ticho, effective as of October 21, 2020.

Exhibit 10.10 CHANGE OF CONTROL SEVERANCE AGREEMENT This Change of Control Severance Agreement (the ?Agreement?), is made and entered into this 21st day of October, 2020 (the ?Effective Date?), by and between Stoke Therapeutics, Inc. (?Stoke?), and Barry Ticho (?Executive?). Recitals: R-1. Stoke and Executive are parties to an Amended and Restated Employment Agreement dated October 21, 2020, (the

Stoke Therapeutics Reports Full Year 2020 Financial Results and Provides Business Updates – First patient dosed in the multiple ascending dose portion of Phase 1/2a MONARCH study of STK-001 in Dravet syndrome – – Preliminary safety and PK data from t

Exhibit 99.1 Stoke Therapeutics Reports Full Year 2020 Financial Results and Provides Business Updates ? First patient dosed in the multiple ascending dose portion of Phase 1/2a MONARCH study of STK-001 in Dravet syndrome ? ? Preliminary safety and PK data from the single ascending dose portion of MONARCH still expected in H2 2021 ? ? As of December 31, 2020, Company had $287.5 million in cash, ca

Amended and Restated Executive Employment Agreement, by and between the Registrant and Barry Ticho, effective as of October 21, 2020.

Exhibit10.7 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the ?Agreement?), is made and entered into this 21st day of October, 2020 (the ?Effective Date?), by and between Stoke Therapeutics, Inc. (?Stoke?), and Barry Ticho (?Executive?). WHEREAS, Stoke and Executive entered into that certain Employment Agreement dated September 11, 20

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. 1)* Stoke Therapeut

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. 1)* Stoke Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 86150R107 (CUSIP Number) December 31, 2020 (Date o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Stoke Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 86150R107 (CUSIP Number) December 31, 20220 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Stoke therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) (CUSIP Number) Dec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Stoke therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 86150R107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, at $0.0001 par value per share, of Stoke Therapeutics

Joint Filing Statement Pursuant to Rule 13d-1(k)(1)

Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No.